Bevacizumab, Fluorouracil, Leucovorin Calcium, and Oxaliplatin Before Surgery in Treating Patients With Stage II-III Rectal Cancer

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

UNKNOWN

Clinical Phase

PHASE2

Total Enrollment

17 participants

Study Classification

INTERVENTIONAL

Study Start Date

2013-08-02

Study Completion Date

2023-06-24

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

This phase II trial studies how well bevacizumab, fluorouracil, leucovorin calcium, and oxaliplatin before surgery works in treating patients with stage II-III rectal cancer. Monoclonal antibodies, such as bevacizumab, can block tumor growth in different ways. Some block the ability of tumor to grow and spread. Others find tumor cells and help kill them or carry tumor-killing substances to them. Drugs used in chemotherapy, such as fluorouracil, leucovorin calcium, and oxaliplatin, work in different ways to stop the growth of tumor cells, either by killing the cells or by stopping them from dividing. Giving bevacizumab together with fluorouracil, leucovorin calcium, and oxaliplatin may be an effective treatment for rectal cancer.

Related Clinical Trials

Explore similar clinical trials based on study characteristics and research focus.

Phase II Trial of FOLFOX6, Bevacizumab and Cetuximab in Patients With Colorectal Cancer

NCT00100841

Adenocarcinoma of the Rectum Mucinous Adenocarcinoma of the Colon Recurrent Colon Cancer +4 more

COMPLETED PHASE2

Neo-adjuvant Chemoradiation With Oxaliplatin/5-FU in Rectal Cancer

NCT00831181

Colorectal Cancer

COMPLETED PHASE2

Postoperative Chemotherapy With or Without Bevacizumab for Patients With Stage II or III Rectal Cancer

NCT00303628

Adenocarcinoma of the Rectum Stage II Rectal Cancer Stage III Rectal Cancer

TERMINATED PHASE3

Combination Chemotherapy and Bevacizumab in Treating Patients With Locally Advanced, Metastatic, or Recurrent Colorectal Cancer

NCT00070122

Adenocarcinoma of the Colon Adenocarcinoma of the Rectum Recurrent Colon Cancer +5 more

TERMINATED PHASE3

A Phase I, Pharmacological, and Biological Study of OSI-774 in Combination With FOLFOX 4 (5-FU, Leucovorin, and Oxaliplatin) and Bevacizumab (Avastin) in Patients With Advanced Colorectal Cancer

NCT00060411

Mucinous Adenocarcinoma of the Colon Mucinous Adenocarcinoma of the Rectum Recurrent Colon Cancer +13 more

COMPLETED PHASE1

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

PRIMARY OBJECTIVES:

I. To determine if six cycles of modified fluorouracil, leucovorin calcium, and oxaliplatin (mFOLFOX7) plus bevacizumab (Avastin) will yield complete pathologic response (cPR) of 25% or more in the primary tumor of patients with stage II and III rectal cancer.

SECONDARY OBJECTIVES:

I. To assess the rate of tumor regression (pathologic stage lower than clinical stage) after 6 cycles of mFOLFOX7 and bevacizumab in the primary rectal cancer.

II. To assess local recurrence rate over 3 years after 6 cycles of mFOLFOX7 and bevacizumab.

TERTIARY OBJECTIVES:

I. Correlation of the following marker with response (defined as CPR or down staging):

* Intratumoral Gene expression and germline polymorphism of genes involved in the vascular endothelial growth factor (VEGF) and VEGF independent pathways (VEGF, vascular endothelial growth factor receptor 1 \[VEGFR1\], VEGFR2, interleukin-8 \[IL8\], chemokine (C-X-C motif) receptor 2 \[CXCR2\], intercellular adhesion molecule \[ICAM\], VEGFR1 and VEGFR2, neuropilin 1 or 2 \[NRP1,2\], cluster of differentiation \[CD\] 44, aldehyde dehydrogenase \[ALDH\], leucine-rich repeats and immunoglobulin-like \[LRIG\].
* Circulating tumor cells (CTC) and VEGF-factor A (A) on the CTC.

II. Prediction of surgical resection margin by pretreatment magnetic resonance imaging (MRI).

OUTLINE:

Patients receive bevacizumab intravenously (IV) over 30-90 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV continuously over 46-48 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after treatment, patients undergo surgery.

After completion of study treatment, patients are followed up every 3 months for 2 years and then every 6 months for 3 years.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

Mucinous Adenocarcinoma of the Rectum Signet Ring Adenocarcinoma of the Rectum Stage IIA Rectal Cancer Stage IIB Rectal Cancer Stage IIC Rectal Cancer Stage IIIA Rectal Cancer Stage IIIB Rectal Cancer Stage IIIC Rectal Cancer

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

NA

Intervention Model

SINGLE_GROUP

Primary Study Purpose

TREATMENT

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Treatment (bevacizumab, mFOLFOX7)

Patients receive bevacizumab IV over 30-90 minutes, oxaliplatin IV over 2 hours, leucovorin calcium IV, and fluorouracil IV continuously over 46-48 hours on day 1. Treatment repeats every 14 days for 6 courses in the absence of disease progression or unacceptable toxicity. Within 6-8 weeks after treatment, patients undergo surgery.

Group Type EXPERIMENTAL

bevacizumab

Intervention Type BIOLOGICAL

Given IV

oxaliplatin

Intervention Type DRUG

Given IV

leucovorin calcium

Intervention Type DRUG

Given IV

fluorouracil

Intervention Type DRUG

Given IV

laboratory biomarker analysis

Intervention Type OTHER

Correlative studies

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

bevacizumab

Given IV

Intervention Type BIOLOGICAL

oxaliplatin

Given IV

Intervention Type DRUG

leucovorin calcium

Given IV

Intervention Type DRUG

fluorouracil

Given IV

Intervention Type DRUG

laboratory biomarker analysis

Correlative studies

Intervention Type OTHER

Other Intervention Names

Discover alternative or legacy names that may be used to describe the listed interventions across different sources.

anti-VEGF humanized monoclonal antibody anti-VEGF monoclonal antibody Avastin rhuMAb VEGF 1-OHP Dacotin Dacplat Eloxatin L-OHP CF CFR LV 5-fluorouracil 5-Fluracil 5-FU

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* Histologically confirmed adenocarcinoma of the rectum in patients with no prior therapy who are candidate for surgical resection
* Tumor lesion is 5-15 cm from anal verge
* cT2 N+ or cT3-T4 N0 or N+ as assessed by endorectal ultrasound scan (US)
* No evidence of distant metastatic disease
* Signed informed consent prior to initiation of any study-specific procedure or treatment
* Eastern Cooperative Oncology Group (ECOG) performance status of 0 or 1
* Able to comply with the protocol, including tissue sampling, imaging studies and surgical intervention
* Life expectancy more than 12 weeks
* Absolute neutrophil count \>= 1500 per mm\^3
* Platelet count \>= 100,000 per mm\^3
* Hemoglobin \>= 9 g/dL (may be transfused to maintain or exceed this level)
* Total bilirubin \< 1.5 x upper limit of normal (ULN)
* Aspartate aminotransferase and alanine aminotransferase \< 2.5 x ULN
* Calculated creatinine clearance according to Cockroft and Gault formula \>= 50 mL/min
* Urine for proteinuria should be \< 2 +; patients discovered to have \>= 2 + proteinuria on dipstick urinalysis at baseline should undergo a 24-hour urine collection and must demonstrate \< 1 g of protein in 24 hours
* International normalized ratio =\< 1.5 and activated prothrombin time =\< 1.5 x ULN within 7 days prior to enrollment; the use of full-dose oral or parenteral anticoagulants is permitted as long as the international normalized ratio (INR) or activated partial thromboplastin time (aPTT) is within therapeutic limits (according to the medical standard of the enrolling institution) and the patient has been on a stable dose of anticoagulants for at least two weeks prior to the first study treatment
* Female patients should not be pregnant or breast-feeding. Female patients, if not postmenopausal (\< 12 months of amenorrhea) or surgically sterile, should agree to use effective, non-hormonal means of contraception (intrauterine contraceptive device, barrier method of contraception in conjunction with spermicidal jelly or surgically sterile) during the study and for a period of at least 6 months following the last administration of study drugs. Female patients with an intact uterus (unless amenorrheic for the last 24 months) must have a negative serum pregnancy test within 7 days prior to randomization into the study
* Fertile male patients must agree to use a highly effective contraceptive method (i.e., with a failure rate of \< 1 % per year, such as vasectomy, sexual abstinence, or female partner's use of hormonal implants or combined oral contraceptives) during the trial and for a period of at least 6 months after the last dose of study drug
* Archival tumor tissue sample must be requested and available prior to study entry; a copy of the local pathology report must be submitted along with the specimens; patients without available archival tissue are excluded

Exclusion Criteria

* Prior chemotherapy or radiotherapy for colorectal cancer
* Clinical evidence of bleeding diathesis or coagulopathy
* Pregnancy or lactation
* Sensory peripheral neuropathy \>= grade 2
* Known positivity for human immunodeficiency virus (HIV)
* Malignancies other than rectal cancer within 5 years prior to randomization, except for adequately treated carcinoma in situ of the cervix, basal or squamous cell skin cancer, localized prostate cancer treated surgically with curative intent, and ductal carcinoma in situ treated surgically with curative intent
* Radiotherapy to any site for any reason within 28 days prior to study entry
* Treatment with any other investigational agent, or participation in another investigational drug trial within 28 days prior to randomization
* Evidence of any other disease, neurological or metabolic dysfunction, physical examination finding, or laboratory finding giving reasonable suspicion of a disease or condition that contraindicates the use of bevacizumab or puts the patient at high risk for treatment-related complications
* Surgery (including open biopsy), significant traumatic injury within 28 days prior to randomization, minor surgery, including insertion of an indwelling catheter, within 24 hours prior to the first bevacizumab infusion is allowed
* Current or recent (within 10 days prior to first dose of bevacizumab) use of aspirin (\> 325 mg/day)
* History or evidence of inherited bleeding diathesis or coagulopathy with a risk of bleeding
* Inadequately controlled hypertension (blood pressure: systolic \> 150 mmHg and/or diastolic \> 100 mmHg)
* Clinically significant (i.e., active) cardiovascular disease (e.g., cerebrovascular accident or myocardial infarction within 6 months prior to randomization), unstable angina, congestive heart failure (New York Heart Association Class \>= II) or serious cardiac arrhythmia that is uncontrolled by medication or may interfere with administration of study treatment
* Serious non-healing wound, active peptic ulcer, or untreated bone fracture
* History of abdominal fistula, gastrointestinal (GI) perforation, or intra-abdominal abscess within 6 months of randomization
* Known hypersensitivity to bevacizumab or any of its excipients or any other study drug

Minimum Eligible Age

18 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No